Ampersand 2018 LP converts preferred into common

Ampersand 2018 Limited Partnership, a 10% owner of Interpace Biosciences, Inc., reported converting preferred stock into common shares.

Rhea-AI Filing Summary

Ampersand 2018 Limited Partnership, a 10% owner of Interpace Biosciences, Inc., reported converting preferred stock into common shares. On January 20, 2026, it converted 28,000 Series C Convertible Preferred shares into 13,861,386 shares of common stock.

The preferred shares had a stated value of $1,000 per share and a conversion price of $2.02 per common share, which determines how many common shares are issued on conversion. Following this transaction, the reporting holder owned 13,861,386 common shares directly and no remaining Series C preferred shares.

Insider Trade Summary

28,000 shares exercised/converted

Exercise 2 txns

Insider Ampersand 2018 Limited Partnership

Role 10% Owner

Type	Security	Shares	Price	Value
Conversion	Series C Convertible Preferred Stock	28,000	$0.00	$0.00
Conversion	Common Stock	13,861,386	$2.02	$28.00M

Holdings After Transaction: Series C Convertible Preferred Stock — 0 contracts (Direct); Common Stock — 13,861,386 shares (Direct)

Footnotes (5)

1. F1. On January 20, 2026, 28,000 shares of the Issuer's Series C Convertible Preferred Stock, par value $0.01 per share (the "Series C Preferred Shares"), were converted into 13,861,386 shares of the Issuer's common stock, par value $0.01 per share (the "Common Stock").
2. F2. The Series C Preferred Shares were convertible into a number of shares of Common Stock equal to the initial stated value per Series C Share of $1,000 divided by the initial conversion price of $2.02 per shares and then multiplied by the number of Series C Preferred Shares to be converted.
3. F3. These securities are held of record by Ampersand 2018 Limited Partnership (the "Investor"). AMP-18 Management Company Limited Partnership ("AMCLP") is the general partner of the Investor, and AMP-18 MC LLC ("AMCLLC") is the general partner of AMCLP. By virtue of such relationships, AMCLP and AMCLLC may be deemed to have voting and investment power with respect to the securities held by the Investor noted above and as a result may be deemed to have beneficial ownership over such securities.
4. F4. Each of the Investor, AMCLP and AMCLLC disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
5. F5. The Series C Preferred Shares had no expiration date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Ampersand 2018 Limited Partnership report for Interpace Biosciences (IDXG)?

Ampersand 2018 Limited Partnership reported converting 28,000 shares of Series C Convertible Preferred Stock into 13,861,386 shares of Interpace Biosciences common stock. This conversion was recorded on January 20, 2026, and left the holder with only common shares and no remaining Series C preferred.

How many Interpace Biosciences (IDXG) common shares were received in the preferred stock conversion?

The filing shows that 13,861,386 shares of Interpace Biosciences common stock were issued upon conversion of 28,000 Series C Convertible Preferred shares. The conversion followed the stated formula using a $1,000 stated value and a $2.02 conversion price per common share.

What are the key terms of the Series C Convertible Preferred Stock for Interpace Biosciences (IDXG)?

Each Series C Preferred share had a stated value of $1,000 and was convertible into common stock at a $2.02 per share conversion price. The number of common shares issued depended on this formula multiplied by the number of Series C shares converted.

How many Interpace Biosciences (IDXG) shares did the reporting holder own after the conversion?

After the reported transaction, the holder beneficially owned 13,861,386 shares of Interpace Biosciences common stock. The filing shows zero derivative (Series C Preferred) shares remaining, meaning the position shifted entirely into common stock as of the transaction date.

Who is the reporting person in this Interpace Biosciences (IDXG) Form 4 and what is their role?

The reporting person is Ampersand 2018 Limited Partnership, identified as a 10% owner of Interpace Biosciences. Related entities AMP-18 Management Company Limited Partnership and AMP-18 MC LLC may be deemed beneficial owners through control relationships, though each party disclaims beneficial ownership beyond any pecuniary interest.

Did the Series C Preferred Stock of Interpace Biosciences (IDXG) have an expiration date?

The filing states that the Series C Preferred Shares had no expiration date. This means the holder could choose when to convert them into common stock, based on the fixed stated value and the $2.02 per share conversion price described in the disclosure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/04/2026 - 06:46 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ampersand 2018 Limited Partnership

(Last) (First) (Middle)

C/O INTERPACE BIOSCIENCES, INC.

WATERVIEW PLAZA, SUITE 310 2001 ROUTE 46

(Street)

PARSIPPANY NJ 07054

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
INTERPACE BIOSCIENCES, INC. [ IDXG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/20/2026(1)		C		13,861,386	A	$2.02(2)	13,861,386	D(3)(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series C Convertible Preferred Stock	$2.02(2)	01/20/2026(1)		C			28,000	10/11/2024	(5)	Common Stock	13,861,386	$0	0	D(3)(4)

Explanation of Responses:

1. On January 20, 2026, 28,000 shares of the Issuer's Series C Convertible Preferred Stock, par value $0.01 per share (the "Series C Preferred Shares"), were converted into 13,861,386 shares of the Issuer's common stock, par value $0.01 per share (the "Common Stock").

2. The Series C Preferred Shares were convertible into a number of shares of Common Stock equal to the initial stated value per Series C Share of $1,000 divided by the initial conversion price of $2.02 per shares and then multiplied by the number of Series C Preferred Shares to be converted.

3. These securities are held of record by Ampersand 2018 Limited Partnership (the "Investor"). AMP-18 Management Company Limited Partnership ("AMCLP") is the general partner of the Investor, and AMP-18 MC LLC ("AMCLLC") is the general partner of AMCLP. By virtue of such relationships, AMCLP and AMCLLC may be deemed to have voting and investment power with respect to the securities held by the Investor noted above and as a result may be deemed to have beneficial ownership over such securities.

4. Each of the Investor, AMCLP and AMCLLC disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

5. The Series C Preferred Shares had no expiration date.

	/s/ Dana L. Niles By: Dana L. Niles, Chief Operating Officer of AMP-18 MC LLC	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.